Skip to main navigation Skip to search Skip to main content

Pharmaceutical development of an intravenous dosage form of diacetylmorphine hydrochloride

  • Marjolein G. Klous
  • , Bastiaan Nuijen
  • , Wim van den Brink
  • , Jan M. van Ree
  • , Jos H. Beijnen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A solid dosage form for multiple use was developed for parenteral administration of diacetylmorphine in a clinical trial on co-prescription of heroin to heroin addicts. A 300-mg/mL diacetylmorphine hydrochloride solution was lyophilised as 10-mL aliquots in 30-mL glass vials, to be reconstituted to 150 mg/mL with water for injection before use. Addition of bulking agents for improvement of the cake structure of the lyophilised product appeared unnecessary. Stability studies indicated good stability of the lyophilised product under prescribed storage conditions (25degreesC, 60% relative humidity) and under more extreme conditions (40degreesC, 75% relative humidity). The reconstituted product was found to be stable for six days at room temperature. Suitability of the product for multiple use was supported by the fact that the reconstituted product was found to be antimicrobially active
Original languageEnglish
Pages (from-to)287-295
JournalPDA journal of pharmaceutical science and technology / PDA
Volume58
Issue number6
Publication statusPublished - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Pharmaceutical development of an intravenous dosage form of diacetylmorphine hydrochloride'. Together they form a unique fingerprint.

Cite this